difelikefalin (Korsuva)
Jump to navigation
Jump to search
Indications
- treatment of moderate-severe pruritus in adults undergoing hemodialysis
Dosage
- 0.5. ug/kg IV bolus injection at the end of hemodialysis
- administer within 60 minutes of syringe preparation
Injection: 50 ug/mL
Adverse effects
- diarrhea, dizziness, nausea, gait disturbances, falls, hyperkalemia, headache, somnolence, mental status change
- drug adverse effects of opiates
- drug adverse effects of psychotropic agents
- drug adverse effects of sedatives
Mechanism of action
- kappa opioid receptor agonist
More general terms
References
- ↑ Weiner DE, Vervloet MG, Walpen S, et al; trial investigators. Safety and effectiveness of difelikefalin in patients with moderate-to-severe pruritus undergoing hemodialysis: an open-label, multicenter study. Kidney Med. 2022;4:100542. PMID: https://pubmed.ncbi.nlm.nih.gov/36185706
- ↑ difelikefalin (Rx) Korsuva https://reference.medscape.com/drug/korsuva-difelikefalin-4000195